<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32778941</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2021</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0533</ISSN><JournalIssue CitedMedium="Internet"><Volume>140</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Acta neuropathologica</Title><ISOAbbreviation>Acta Neuropathol</ISOAbbreviation></Journal><ArticleTitle>Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLD-TDP subtypes.</ArticleTitle><Pagination><StartPage>645</StartPage><EndPage>658</EndPage><MedlinePgn>645-658</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00401-020-02207-w</ELocationID><Abstract><AbstractText>Aggregation of hyperphosphorylated TDP-43 is the hallmark pathological feature of the most common molecular form of frontotemporal lobar degeneration (FTLD-TDP) and in the vast majority of cases with amyotrophic lateral sclerosis (ALS-TDP). However, most of the specific phosphorylation sites remain to be determined, and their relevance regarding pathogenicity and clinical and pathological phenotypic diversity in FTLD-TDP and ALS-TDP remains to be identified. Here, we generated a novel antibody raised against TDP-43 phosphorylated at serine 375 (pTDP-43<sup>S375</sup>) located in the low-complexity domain, and used it to investigate the presence of S375 phosphorylation in a series (n&#x2009;=&#x2009;44) of FTLD-TDP and ALS-TDP cases. Immunoblot analysis demonstrated phosphorylation of S375 to be a consistent feature of pathological TDP-43 species, including full-length and C-terminal fragments, in all FTLD-TDP subtypes examined (A-C) and in ALS-TDP. Of particular interest, however, detailed immunohistochemical analysis showed striking differences in the immunoreactivity profile of inclusions with the pTDP-43<sup>S375</sup> antiserum among pathological subtypes. TDP-43 pathology of ALS-TDP, FTLD-TDP type B (including cases with the C9orf72 mutation), and FTLD-TDP type C all showed strong pTDP-43<sup>S375</sup> immunoreactivity that was similar in amount and morphology to that seen with an antibody against TDP-43 phosphorylated at S409/410 used as the gold standard. In stark contrast, TDP-43 pathology in sporadic and genetic forms of FTLD-TDP type A (including cases with GRN and C9orf72 mutations) was found to be almost completely negative by pTDP-43<sup>S375</sup> immunohistochemistry. These data suggest a subtype-specific, conformation-dependent binding of pTDP-43<sup>S375</sup> antiserum to TDP-43 aggregates, consistent with the idea of distinct structural TDP-43 conformers (i.e., TDP-43 strains) as the molecular basis for the phenotypic diversity in TDP-43 proteinopathies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Manuela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6232-4057</Identifier><AffiliationInfo><Affiliation>Molecular Neuropathology of Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen, Otfried-M&#xfc;llerstr. 23, 72072, T&#xfc;bingen, Germany. manuela.neumann@dzne.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neuropathology, University Hospital of T&#xfc;bingen, T&#xfc;bingen, Germany. manuela.neumann@dzne.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frick</LastName><ForeName>Petra</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Molecular Neuropathology of Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen, Otfried-M&#xfc;llerstr. 23, 72072, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paron</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Molecular Pathology, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosten</LastName><ForeName>Jonas</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Molecular Neuropathology of Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE) T&#xfc;bingen, Otfried-M&#xfc;llerstr. 23, 72072, T&#xfc;bingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buratti</LastName><ForeName>Emanuele</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Molecular Pathology, International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackenzie</LastName><ForeName>Ian R</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Department of Pathology, University of British Columbia and Vancouver General Hospital, Vancouver, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Acta Neuropathol</MedlineTA><NlmUniqueID>0412041</NlmUniqueID><ISSNLinking>0001-6322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D066329">Protein Aggregates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C566288">Frontotemporal Dementia With Motor Neuron Disease</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Acta Neuropathol. 2020 Nov 3;:</RefSource><PMID Version="1">33141274</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="N">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066329" MajorTopicYN="N">Protein Aggregates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066263" MajorTopicYN="N">Protein Aggregation, Pathological</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">Conformation-specific</Keyword><Keyword MajorTopicYN="N">Frontotemporal dementia</Keyword><Keyword MajorTopicYN="N">Frontotemporal lobar degeneration</Keyword><Keyword MajorTopicYN="N">Phosphorylation-specific antibody</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">TDP-43 strains</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32778941</ArticleId><ArticleId IdType="pmc">PMC7547034</ArticleId><ArticleId IdType="doi">10.1007/s00401-020-02207-w</ArticleId><ArticleId IdType="pii">10.1007/s00401-020-02207-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. TDP-43 post-translational modifications in health and disease. Expert Opin Ther Targets. 2018;22:279&#x2013;293. doi: 10.1080/14728222.2018.1439923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2018.1439923</ArticleId><ArticleId IdType="pubmed">29431050</ArticleId></ArticleIdList></Reference><Reference><Citation>Guenther EL, Cao Q, Trinh H, Lu J, Sawaya MR, Cascio D, et al. Atomic structures of TDP-43 LCD segments and insights into reversible or pathogenic aggregation. Nat Struct Mol Biol. 2018;25:463&#x2013;471. doi: 10.1038/s41594-018-0064-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41594-018-0064-2</ArticleId><ArticleId IdType="pmc">PMC5990464</ArticleId><ArticleId IdType="pubmed">29786080</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64:60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Hock EM, Polymenidou M. Prion-like propagation as a pathogenic principle in frontotemporal dementia. J Neurochem. 2016;138(Suppl 1):163&#x2013;183. doi: 10.1111/jnc.13668.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13668</ArticleId><ArticleId IdType="pmc">PMC6680357</ArticleId><ArticleId IdType="pubmed">27502124</ArticleId></ArticleIdList></Reference><Reference><Citation>Inukai Y, Nonaka T, Arai T, Yoshida M, Hashizume Y, Beach TG, et al. Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett. 2008;582:2899&#x2013;2904. doi: 10.1016/j.febslet.2008.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2008.07.027</ArticleId><ArticleId IdType="pubmed">18656473</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, et al. TDP-43 is a key player in the clinical features associated with Alzheimer&#x2019;s disease. Acta Neuropathol. 2014;127:811&#x2013;824. doi: 10.1007/s00401-014-1269-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1269-z</ArticleId><ArticleId IdType="pmc">PMC4172544</ArticleId><ArticleId IdType="pubmed">24659241</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, Nonaka T, Suzuki T, Arai T, Dohmae N, Akiyama H, et al. Identification of casein kinase-1 phosphorylation sites on TDP-43. Biochem Biophys Res Commun. 2009;382:405&#x2013;409. doi: 10.1016/j.bbrc.2009.03.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.03.038</ArticleId><ArticleId IdType="pubmed">19285963</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, Obi T, Shishido T, Akatsu H, Murayama S, Saito Y, et al. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci Rep. 2016;6:23281. doi: 10.1038/srep23281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23281</ArticleId><ArticleId IdType="pmc">PMC4793195</ArticleId><ArticleId IdType="pubmed">26980269</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami I, Arai T, Hasegawa M. The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. Acta Neuropathol. 2019;138:751&#x2013;770. doi: 10.1007/s00401-019-02077-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02077-x</ArticleId><ArticleId IdType="pmc">PMC6800885</ArticleId><ArticleId IdType="pubmed">31555895</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferriere F, Maniecka Z, Perez-Berlanga M, Hruska-Plochan M, Gilhespy L, Hock EM, et al. TDP-43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat Neurosci. 2019;22:65&#x2013;77. doi: 10.1038/s41593-018-0294-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41593-018-0294-y</ArticleId><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Porta S, Michael Baer G, Xu Y, Suh E, Kwong LK, et al. Expansion of the classification of FTLD&#x2013;TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. 2017;134:65&#x2013;78. doi: 10.1007/s00401-017-1679-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1679-9</ArticleId><ArticleId IdType="pmc">PMC5521959</ArticleId><ArticleId IdType="pubmed">28130640</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M. Reappraisal of TDP-43 pathology in FTLD-U subtypes. Acta Neuropathol. 2017;134:79&#x2013;96. doi: 10.1007/s00401-017-1716-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-017-1716-8</ArticleId><ArticleId IdType="pubmed">28466142</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M. Subcortical TDP-43 pathology patterns validate cortical FTLD&#x2013;TDP subtypes and demonstrate unique aspects of C9orf72 mutation cases. Acta Neuropathol. 2020;139:83&#x2013;98. doi: 10.1007/s00401-019-02070-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02070-4</ArticleId><ArticleId IdType="pubmed">31501924</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Baborie A, Pickering-Brown S, Du Plessis D, Jaros E, Perry RH, et al. Heterogeneity of ubiquitin pathology in frontotemporal lobar degeneration: classification and relation to clinical phenotype. Acta Neuropathol. 2006;112:539&#x2013;549. doi: 10.1007/s00401-006-0138-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0138-9</ArticleId><ArticleId IdType="pmc">PMC2668618</ArticleId><ArticleId IdType="pubmed">17021754</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, et al. A harmonized classification system for FTLD&#x2013;TDP pathology. Acta Neuropathol. 2011;122:111&#x2013;113. doi: 10.1007/s00401-011-0845-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-011-0845-8</ArticleId><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Mackenzie IR, Cairns NJ, Boyer PJ, Markesbery WR, Smith CD. TDP-43 in the ubiquitin pathology of frontotemporal dementia with VCP gene mutations. J Neuropathol Exp Neurol. 2007;66:152&#x2013;157. doi: 10.1097/nen.0b013e31803020b9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/nen.0b013e31803020b9</ArticleId><ArticleId IdType="pubmed">17279000</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149. doi: 10.1007/s00401-008-0477-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0477-9</ArticleId><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Newell K, Paron F, Mompean M, Murrell J, Salis E, Stuani C, et al. Dysregulation of TDP-43 intracellular localization and early onset ALS are associated with a TARDBP S375G variant. Brain Pathol. 2019;29:397&#x2013;413. doi: 10.1111/bpa.12680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12680</ArticleId><ArticleId IdType="pmc">PMC6875182</ArticleId><ArticleId IdType="pubmed">30461104</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishihira Y, Gefen T, Mao Q, Appin C, Kohler M, Walker J, et al. Revisiting the utility of TDP-43 immunoreactive (TDP-43-ir) pathology to classify FTLD&#x2013;TDP subtypes. Acta Neuropathol. 2019;138:167&#x2013;169. doi: 10.1007/s00401-019-02024-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02024-w</ArticleId><ArticleId IdType="pmc">PMC7186909</ArticleId><ArticleId IdType="pubmed">31065833</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, Masuda-Suzukake M, Arai T, Hasegawa Y, Akatsu H, Obi T, et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 2013;4:124&#x2013;134. doi: 10.1016/j.celrep.2013.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.06.007</ArticleId><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Porta S, Xu Y, Restrepo CR, Kwong LK, Zhang B, Brown HJ, et al. Patient-derived frontotemporal lobar degeneration brain extracts induce formation and spreading of TDP-43 pathology in vivo. Nat Commun. 2018;9:4220. doi: 10.1038/s41467-018-06548-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-06548-9</ArticleId><ArticleId IdType="pmc">PMC6181940</ArticleId><ArticleId IdType="pubmed">30310141</ArticleId></ArticleIdList></Reference><Reference><Citation>Pottier C, Ravenscroft TA, Sanchez-Contreras M, Rademakers R. Genetics of FTLD: overview and what else we can expect from genetic studies. J Neurochem. 2016;138(Suppl 1):32&#x2013;53. doi: 10.1111/jnc.13622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13622</ArticleId><ArticleId IdType="pubmed">27009575</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampathu DM, Neumann M, Kwong LK, Chou TT, Micsenyi M, Truax A, et al. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol. 2006;169:1343&#x2013;1352. doi: 10.2353/ajpath.2006.060438.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2006.060438</ArticleId><ArticleId IdType="pmc">PMC1780184</ArticleId><ArticleId IdType="pubmed">17003490</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinagawa S, Naasan G, Karydas AM, Coppola G, Pribadi M, Seeley WW, et al. Clinicopathological study of patients with C9ORF72-associated frontotemporal dementia presenting with delusions. J Geriatr Psychiatry Neurol. 2015;28:99&#x2013;107. doi: 10.1177/0891988714554710.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0891988714554710</ArticleId><ArticleId IdType="pmc">PMC4408221</ArticleId><ArticleId IdType="pubmed">25342578</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi R, Tada M, Shiga A, Toyoshima Y, Konno T, Sato T, et al. Heterogeneity of cerebral TDP-43 pathology in sporadic amyotrophic lateral sclerosis: Evidence for clinico-pathologic subtypes. Acta Neuropathol Commun. 2016;4:61. doi: 10.1186/s40478-016-0335-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40478-016-0335-2</ArticleId><ArticleId IdType="pmc">PMC4918136</ArticleId><ArticleId IdType="pubmed">27338935</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Shepherd CE, Kril JJ, McCann H, McGeachie A, McGinley C, et al. Classification of FTLD&#x2013;TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. Acta Neuropathol Commun. 2013;1:33. doi: 10.1186/2051-5960-1-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2051-5960-1-33</ArticleId><ArticleId IdType="pmc">PMC4046675</ArticleId><ArticleId IdType="pubmed">24252630</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuji H, Arai T, Kametani F, Nonaka T, Yamashita M, Suzukake M, et al. Molecular analysis and biochemical classification of TDP-43 proteinopathy. Brain. 2012;135:3380&#x2013;3391. doi: 10.1093/brain/aws230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aws230</ArticleId><ArticleId IdType="pubmed">23035040</ArticleId></ArticleIdList></Reference><Reference><Citation>Woollacott IO, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. J Neurochem. 2016;138(Suppl 1):6&#x2013;31. doi: 10.1111/jnc.13654.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jnc.13654</ArticleId><ArticleId IdType="pubmed">27144467</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>